Present and future of FDG-PET/CT in ovarian cancer

被引：30
作者：
Kitajima, Kazuhiro [1 ]
Murakami, Koji [2 ]
Sakamoto, Setsu [3 ]
Kaji, Yasushi [4 ]
Sugimura, Kazuro [5 ]
机构：
[1] Inst Biomed Res & Innovat, Dept PET Diag, Chuo Ku, Kobe, Hyogo 6500047, Japan
[2] Keio Univ, Sch Med, Div Nucl Med, Dept Diagnost Radiol, Tokyo, Japan
[3] Dokkyo Med Univ Hosp, PET Ctr, Mibu, Tochigi, Japan
[4] Dokkyo Univ, Sch Med, Dept Radiol, Mibu, Tochigi 32102, Japan
[5] Kobe Univ, Dept Radiol, Grad Sch Med, Kobe, Hyogo 657, Japan
来源：
ANNALS OF NUCLEAR MEDICINE | 2011年 / 25卷 / 03期
关键词：
FDG; PET/CT; Ovarian cancer; Staging; Restaging; POSITRON-EMISSION-TOMOGRAPHY; PET/CONTRAST-ENHANCED CT; RECURRENT OVARIAN; COMPUTED-TOMOGRAPHY; F-18-FDG PET/CT; NEOADJUVANT CHEMOTHERAPY; DIAGNOSTIC-ACCURACY; INTEGRATED PET/CT; THERAPY RESPONSE; NEXT-GENERATION;
D O I：
10.1007/s12149-010-0449-8
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Integrated FDG-PET/CT has been used successfully for the diagnosis, staging, restaging, therapy monitoring and prognostic prediction of ovarian cancer as well as various other malignant tumors. Compared with conventional PET/non-contrast CT images, combined PET/contrast-enhanced CT images with intravenous iodine contrast medium and sufficient radiation dose may contribute to a more accurate diagnosis with higher confidence. In the future, tracers other than FDG and integrated PET/MRI will be realized. We herein review the place and role of FDG-PET/CT in the management of ovarian cancer, discussing its usefulness and limitations in the imaging of these patients.
引用
收藏
页码：155 / 164
页数：10
相关论文
共 59 条
  • [1] MRI of sonographically indeterminate adnexal masses
    Adusumilli, Saroja
    Hussain, Hero K.
    Caoili, Elaine M.
    Weadock, William J.
    Murray, John P.
    Johnson, Timothy D.
    Chen, Qixuan
    Desjardins, Benoit
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 187 (03) : 732 - 740
  • [2] Combined PET/MRI: a new dimension in whole-body oncology imaging?
    Antoch, Gerald
    Bockisch, Andreas
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : 113 - 120
  • [3] Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer
    Avril, N
    Sassen, S
    Schmalfeldt, B
    Naehrig, J
    Rutke, S
    Weber, WA
    Werner, M
    Graeff, H
    Schwaiger, M
    Kuhn, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7445 - 7453
  • [4] Contribution of whole-body 18FDG PET imaging in the management of cervical cancer
    Belhocine, T
    Thille, A
    Fridman, V
    Albert, A
    Seidel, L
    Nickers, P
    Kridelka, F
    Rigo, P
    [J]. GYNECOLOGIC ONCOLOGY, 2002, 87 (01) : 90 - 97
  • [5] Beyer T, 2000, J NUCL MED, V41, P1369
  • [6] BOOTH SJ, 2008, BJOG, V15, P894
  • [7] Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes
    Bristow, RE
    Giuntoli, RL
    Pannu, HK
    Schulick, RD
    Fishman, EK
    Wahl, RL
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 99 (02) : 294 - 300
  • [8] Bristow RE, 2000, CANCER, V89, P1532, DOI 10.1002/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO
  • [9] 2-A
  • [10] Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT
    Bristow, RE
    del Carmen, MG
    Pannu, HK
    Cohade, C
    Zahurak, ML
    Fishman, EK
    Wahl, RL
    Montz, FJ
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (03) : 519 - 528
123456